Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03839524 · ClinicalTrials.gov registry record · Phase 1
A Trial Evaluating TG4050 in Ovarian Carcinoma.
A Phase 1 study, sponsored by Transgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03839524 is a Phase 1 study that has completed, run by Transgene. The registered enrollment target is 64 participants.
The verdict
NCT03839524, a Phase 1 study, has completed, sponsored by Transgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Interventions
- DRUG TG4050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2024-10-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03839524
The ClinicalTrials.gov registry entry for NCT03839524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Transgene, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TG4050 is the first listed.
NCT03839524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03839524 about?
NCT03839524 is a clinical study titled "A Trial Evaluating TG4050 in Ovarian Carcinoma.". This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
What is the current status of trial NCT03839524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2019-12-09. Estimated completion is 2024-10-08.
What interventions are being tested in trial NCT03839524?
The interventions under investigation include: TG4050 (DRUG).
Who is sponsoring clinical trial NCT03839524?
This trial is sponsored by Transgene, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.